3
FDA-approved indications
27,000+
patients treated through January 2023
$538M
annual net revenues (2022)
$206M
annual R&D investments (2022)
4
phase 3 trials in new indications
press releases
events and presentations
Nov 29, 2023
Piper Sandler Healthcare Conference
Oct 26, 2023
Novocure Q3 2023 Earnings Conference Call
view all
latest filings
view all
reports
See our online annual reports and more.
2022
annual materials
2021
annual materials
2020
annual report and ESG report
mission, vision and values
mission
Together with our patients, we strive to extend survival in some of the most aggressive forms of cancer by developing and commercializing our innovative therapy.
vision
Patient-forward: aspiring to make a difference in cancer
learn morecontact us
investorinfo@novocure.com
610-723-7427
sign up for email alerts
To receive notifications via email, enter your email address and select at least one subscription below. After submitting your information, you will receive an email. You must click the link in the email to activate your subscription. You can sign up for additional subscriptions at any time.
"*" indicates required fields